Leap Therapeutics stock holds steady as Phase 3 sirexatamab plan advances
Published on 09/04/2026 at 18:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Leap Therapeutics stock (ISIN US52195E1029) is trading on the Nasdaq at a market capitalization of about USD 84.95 million as of September 3, 2026, according to market data compiled by MarketBeat.
Market valuation and recent metrics
According to MarketBeat data on Leap Therapeutics, the company carries a market capitalization of USD 84.95 million based on 41,440,000 outstanding shares as of August 31, 2026.
The same overview shows that Leap Therapeutics reported a trailing twelve-month net loss of USD 67.56 million, translating into earnings per share of negative USD 1.22 over that period and a return on equity of negative 247.44 percent, underlining how deeply loss-making the biotechnology group remains as of the current fiscal year.
Balance sheet and book value context
MarketBeat’s figures also indicate that Leap Therapeutics has a book value of USD 0.91 per share, so at recent prices the stock trades at a low price-to-book multiple for a clinical-stage biotech.
With a current ratio and quick ratio both at 1.34, Leap Therapeutics shows cash and near-cash resources that modestly exceed short-term liabilities as of the latest reporting period, which matters for investors assessing funding for the upcoming Phase 3 program.
More on Leap Therapeutics stock and filings
For additional regulatory filings, price history and company documents on Leap Therapeutics stock, visit the dedicated topic page and the company’s investor relations portal.
Sirexatamab moves into planned Phase 3 trial
A recent clinical update for a different company highlights Leap Therapeutics’ progress with its lead antibody sirexatamab: in a news report dated September 4, 2026, RTTNews notes that Leap Therapeutics has reached alignment with the US Food and Drug Administration on a proposed registrational Phase 3 trial of sirexatamab in DKK1-high, second-line metastatic colorectal cancer.
According to the same RTTNews clinical report dated September 4, 2026, the planned randomized Phase 3 study will enroll about 270 patients and compare sirexatamab combined with chemotherapy and bevacizumab against chemotherapy and bevacizumab alone in DKK1-high, second-line metastatic colorectal cancer, positioning the program for a potential accelerated approval based on objective response rate in an initial patient group.
The report further states that overall survival in the full study population could later support full approval, and that the FDA granted Fast Track designation to sirexatamab in May 2026, which gives the Leap Therapeutics program a regulatory pathway designed to speed the review of therapies addressing serious conditions.
Product focus: sirexatamab in colorectal cancer
Sirexatamab is Leap Therapeutics’ investigational monoclonal antibody targeting DKK1, a protein implicated in tumor growth and immune modulation, and the planned Phase 3 trial in DKK1-high, second-line metastatic colorectal cancer is intended to confirm the clinical benefit suggested by earlier-stage data.
For retail investors, the key point is that the sirexatamab program now sits at the threshold of late-stage development, with Fast Track designation and a clear Phase 3 blueprint in place, while Leap Therapeutics still reports substantial losses and relies on its cash reserves and capital markets access to finance ongoing trials.
Stock price context and investor view
MarketBeat’s overview as of August 31, 2026 lists Leap Therapeutics under the Nasdaq biotechnology sector, but recent trading data and a precise closing price for September 4, 2026 were not highlighted in the sources considered here; what is visible, however, is that the company’s market capitalization of USD 84.95 million and book value of USD 0.91 per share as of late August 2026 frame how the market currently values its pipeline and cash position relative to the sizeable trailing net loss of USD 67.56 million.
Leap Therapeutics stock at a glance
- Company: Leap Therapeutics Inc.
- ISIN: US52195E1029
- Ticker: LPTX
- Trading venue: NASDAQ
- Market capitalization: 84,950,000 USD (as of August 31, 2026)
- Sector / Industry: Healthcare / Biotechnology
- Index membership: NASDAQ Biotechnology universe
